
Absci Corp — Investor Relations & Filings
Absci Corp. is a generative AI drug creation company focused on developing biologic medicines. The company's Integrated Drug Creation Platform combines artificial intelligence with scalable wet lab technologies to design and validate novel therapeutics. This platform operates through iterative cycles of data generation, AI model training, de novo design of biologics like antibodies, and experimental validation. Absci's capabilities also include AI-enabled target discovery using a proprietary 'Reverse Immunology' approach. As a clinical-stage company, it advances an internal pipeline and collaborates with pharmaceutical partners to accelerate the development of differentiated biologics for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - Absci Corp (0001672688) (Filer) | 2026-04-22 | English | |
| SCHEDULE 13D/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | |
| SCHEDULE 13G/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | |
| S-8 - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | |
| 10-K - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | |
| 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 35398073 | ARS - Absci Corp (0001672688) (Filer) | 2026-04-22 | English | ||
| 33052408 | SCHEDULE 13D/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | ||
| 33048944 | SCHEDULE 13G/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | ||
| 33035253 | S-8 - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | ||
| 33035179 | 10-K - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | ||
| 32896336 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English | ||
| 32896337 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English | ||
| 32896338 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-25 | English | ||
| 32896339 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-04 | English | ||
| 32896340 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-04 | English | ||
| 31233301 | 4 Filing | 2026-02-04 | English | ||
| 31233143 | 4 Filing | 2026-02-04 | English | ||
| 31233276 | SCHEDULE 13G Filing | 2026-01-30 | English | ||
| 31233114 | 4 Filing | 2026-01-30 | English | ||
| 12952145 | 8-K | 2026-01-14 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ACTINOGEN MEDICAL LIMITED
Developing cortisol-inhibiting therapies for Alzheimer's an…
|
ACW | AU | Professional, scientific and te… |
|
Active Biotech
Biotechnology company developing drugs for oncology and inf…
|
ACTI | SE | Professional, scientific and te… |
|
Adagene Inc.
Clinical-stage biotech developing antibody-based immunother…
|
ADAG | KY | Professional, scientific and te… |
|
ADALTA LIMITED
Clinical-stage biotech developing i-body protein therapeuti…
|
1AD | AU | Professional, scientific and te… |
|
Adaptive Biotechnologies Corp
Decodes the adaptive immune system to develop products for …
|
ADPT | US | Professional, scientific and te… |
|
Adeia Inc.
R&D company that licenses IP for the media, entertainment, …
|
ADEA | US | Professional, scientific and te… |
|
Aditxt, Inc.
Acquires, develops, and deploys health technologies to addr…
|
ADTX | US | Professional, scientific and te… |
|
Advanced Biomed Inc.
Develops microfluidic biochip diagnostic systems for precis…
|
ADVB | US | Professional, scientific and te… |
|
Advanced Proteome Therapeutics Corporation
Develops proprietary technology for chemical modification o…
|
APC.H | CA | Professional, scientific and te… |
|
AIM ImmunoTech Inc.
Immuno-pharma company developing therapeutics for oncology,…
|
AIM | US | Professional, scientific and te… |
Absci Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32931/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32931 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32931 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32931 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32931}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Absci Corp (id: 32931)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.